1. In comparison to vehicle-control, a greater proportion of patients using ruxolitinib achieved a reduction in facial Vitiligo Area Scoring ...
Click to read this study in the Journal of the American Academy of Dermatology.
1. Ruxolitinib was shown to significantly improve failure-free survival for glucocorticoid-refractory chronic graft-versus-host disease (GVHD) compared to control therapy. 2. ...
1. Ruxolitinib was shown to significantly improve failure-free survival for glucocorticoid-refractory chronic graft-versus-host disease (GVHD) compared to control therapy. 2. ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.